Multi-system (rail)

SkyHive Human Capital Operating System Now an Open Platform for Developers

Retrieved on: 
Thursday, November 16, 2023
Professional Services, Apps, Applications, Technology, Human Resources, Software, Artificial Intelligence, Arm, Best Buy, Acquisition, Organization, SAP, Ecosystem, Intelligence, Merck, Machine learning, API, Patent, School, Accenture, Pragmatism, LHH, Lighthouse, Deutsche Bank, Microsoft, Multi-system (rail), Architecture, Management, Video game, SkyHive

SkyHive , a generative artificial intelligence software company that rapidly reskills companies and communities worldwide, today announced that its Human Capital Operating System (™) is now accessible as an open platform for developers across the globe.

Key Points: 
  • SkyHive , a generative artificial intelligence software company that rapidly reskills companies and communities worldwide, today announced that its Human Capital Operating System (™) is now accessible as an open platform for developers across the globe.
  • SkyHive's transition to an open platform model marks a strategic evolution from a more controlled, purpose-driven development approach to one that is broader and application-driven.
  • SkyHive’s intelligence, which has been leveraged for core products internally, will now be an accessible function for third-party application development.
  • “The future of skills is a multi-system and complex ecosystem that requires flexible, powerful technology,” says SkyHive Founder and CEO Sean Hinton.

UiPath and Teradata Partner to Help Businesses Automate Data-Driven Insights for ESG Initiatives

Retrieved on: 
Monday, October 2, 2023
Professional Services, Data Management, Environmental, Social and Governance (ESG), Technology, Other Technology, Software, Artificial Intelligence, LLM, Maintenance, Partnership, Senior, Face, Workflow, Carbon footprint, Multi-system (rail), Business, TDC, Organization, Biophysical environment, ESG, AI, Ecosystem, Environment, Worldwide Partners, NYSE, Automation, Customer service, UiPath, Teradata

Data-driven insights are valuable for environmental, social and governance (ESG) initiatives, with Teradata and UiPath uniquely positioned to drive positive impact by helping customers advance their ESG ambitions through the power of data harmonization across the enterprise.

Key Points: 
  • Data-driven insights are valuable for environmental, social and governance (ESG) initiatives, with Teradata and UiPath uniquely positioned to drive positive impact by helping customers advance their ESG ambitions through the power of data harmonization across the enterprise.
  • The wave of innovation spurred by generative AI and LLMs requires businesses to improve their data harmonization and analytics capabilities.
  • UiPath customers are expected to benefit from Teradata’s expertise in enabling organizations to activate data and analytics, including for AI, at scale.
  • Teradata and UiPath can help customers scale beyond proof-of-concept to deliver automation — and innovation — across the enterprise,” said Lisa Stewart, Senior Vice President, Worldwide Partners and Alliances at Teradata.

VisionTek Unveils VT4950 KVM Docking Station: A Triple-Display, Dual-System Solution Tailored for Today's Professional and Remote Work Environments

Retrieved on: 
Tuesday, July 25, 2023
Hardware, Audio, Video, Consumer Electronics, Mobile, Wireless, Technology, Workflow, KVM, Multi-system (rail), Software, Multimedia, HDMI, FAQ, DisplayPort, Personal computer, Compatibility, USB-C, 2.0, Video game, Mobile phone, Television, Macs

VisionTek Products LLC (VisionTek®), a recognized leader in the field of high-performance upgrades and accessories for PCs and Macs, today announced the introduction of the VisionTek VT4950 KVM docking station.

Key Points: 
  • VisionTek Products LLC (VisionTek®), a recognized leader in the field of high-performance upgrades and accessories for PCs and Macs, today announced the introduction of the VisionTek VT4950 KVM docking station.
  • View the full release here: https://www.businesswire.com/news/home/20230725618949/en/
    This innovative product is the upgraded successor to the previously celebrated VT4900 KVM docking station and is designed to enhance the workflow of users in today's professional and remote work environments.
  • "VisionTek recognizes the increasing complexity of modern workspaces, particularly with the rise of remote work and the need for multi-system usage," said Michael Innes, president of VisionTek.
  • "The VT4950 is our response to these challenges, offering a solution that makes multi-system management incredibly convenient."

MHI Thermal Systems Develops Electric-Driven Transport Refrigeration Units with Heat-Pump Heating System for Domestic EV Trucks

Retrieved on: 
Thursday, March 30, 2023
Carbon, Food, EV, Mitsubishi Heavy Industries, Multi-system (rail), Temperature, EVS, Plant, Running, MHI, Heat, CO2, Heating, ventilation, and air conditioning

Sales of the new unit will be launched for use in production model EV trucks made by domestic automakers.

Key Points: 
  • Sales of the new unit will be launched for use in production model EV trucks made by domestic automakers.
  • In contrast to conventional systems in which the transport refrigeration unit is powered by the vehicle's engine or a dedicated refrigerator engine, the TEJ35AM features an electric drive system that enables operation driven by electric power from the EV alone.
  • The adoption of heat-pump heating, in which ambient heat is used for the heating operation, enables the TEJ35AM to perform heating and cooling operations simultaneously.
  • In these and other ways, the Company will dedicate its resources to the realization of optimal thermal solutions to meet the diverse needs of its customers.

Nature's Answer Introduces Natural Mullein-X™ Cough^ Syrup to Support a Healthy Respiratory System*

Retrieved on: 
Monday, February 6, 2023
Olive, Sambucus, Disease, Ayurveda, Agent handling, Mucus, Passiflora, Catherine Disher, Marshmallow, Sleep, History, Demulcent, Verbascum, Nature, Olive leaf, Grapefruit seed extract, FDA, Relaxation, Liquorice, Multi-system (rail), Chamomile, Zinc, Herbarium, Throat, Trade, Answer, Irritant, Halls (cough drop), Dietary supplement, Glass wool, Elecampane

Nature's Answer Mullein-X™ Cough Syrup is a natural blend of key herbal ingredients that was developed utilizing modern and traditional herbology perfected by Nature's Answer for over 50 years.

Key Points: 
  • Nature's Answer Mullein-X™ Cough Syrup is a natural blend of key herbal ingredients that was developed utilizing modern and traditional herbology perfected by Nature's Answer for over 50 years.
  • Mullein-X™ Cough Syrup is formulated to help clear mucus, help soothe the throat and support immune and upper respiratory health.
  • Nature's Answer Mullein-X™ Immune and Relax Support is a natural blend of key herbal ingredients inspired to help support upper respiratory health, immune health and relaxation day or night.
  • *
    Nature's Answer Mullein-X™ Throat Spray On The Go is a natural herbal blend inspired and developed to help soothe the throat, clear mucus, and support upper respiratory health.

PROCEPT BioRobotics Reports Third Quarter 2022 Financial Results and Increases 2022 Revenue Guidance

Retrieved on: 
Thursday, November 3, 2022
Man, Annual report, Company, BPH, Research, Growth, International, Investment, GAAP, GLOBE, Form 10-K, Webcast, EBITDA, COVID-19, Benign prostatic hyperplasia, Nasdaq, Tax, LUTS, Health, U.S. Securities and Exchange Commission, Forward-looking statement, Providence, Security (finance), Multi-system (rail), Depreciation, SEC, Achievement, Biorobotics, Patient, Prostate, Solution, Medical device, Video game, Pharmaceutical industry, Bookkeeping, Broadcasting, Risk management, Aquablation therapy

Revenue for the third quarter of 2022 was $20.3 million, an increase of 135% compared to the prior year period.

Key Points: 
  • Revenue for the third quarter of 2022 was $20.3 million, an increase of 135% compared to the prior year period.
  • The increase was primarily driven by U.S revenues, including both system sales to new hospital customers and increased handpiece revenue.
  • U.S. handpiece and consumable revenue for the quarter was $8.0 million, an increase of 267% compared to the prior year period.
  • Operating expenses in the third quarter of 2022 were $32.3 million, compared with $17.0 million in the prior year period.

Providence Advances Surgical Robotics Program with Multi-System, National Contract for PROCEPT BioRobotics AquaBeam Systems

Retrieved on: 
Monday, September 19, 2022
Adoption, Health, Benign prostatic hyperplasia, Safety, Risk, LUTS, Organization, Company, Catholic (term), Prostate, Forward-looking statement, U.S. Securities and Exchange Commission, Quality of life, Solution, Multi-system (rail), Nasdaq, Map, Robotics, Surgeon, Caregiver, Security (finance), GLOBE, SEC, Hospital, Man, Urology, Annual report, BPH, Medical device, Medical imaging, Aquablation therapy

REDWOOD CITY, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, and Providence, a not-for-profit health system serving the Western U.S., today announced a multi-system, national contract to acquire AquaBeam Robotic Systems.

Key Points: 
  • REDWOOD CITY, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, and Providence, a not-for-profit health system serving the Western U.S., today announced a multi-system, national contract to acquire AquaBeam Robotic Systems.
  • As of June 30, 2022, Providence had seven AquaBeam Robotic Systems installed across California and Texas.
  • This option appeals to men who are looking for a long-lasting solution with minimal risk of irreversible complications.
  • Aquablation therapy combines real-time, multi-dimensional imaging, automated robotics and heat-free waterjet ablation for targeted, controlled and immediate removal of prostate tissue.

Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

Retrieved on: 
Tuesday, August 2, 2022
Patient, Death, Neutrophilia, Phenotype, GLOBE, Water, LAD, Protein, Forward-looking statement, SEC, FTD, Birth, Biomarker, Probability, Private Securities Litigation Reform Act, SLX, Psychomotor retardation, Leukocytosis, ODD, Glycosylation, Lists of diseases, Therapy, COVID-19, Safety, Efficacy, Multi-system (rail), Quality of life, Drug development, Disease, Company, Nasdaq, Red blood cell, PRV, Program, Glycoprotein, Priority review, API, Hypotonia, CDG, Selectin, Pharmaceutical industry, Crossover, MD

AVTX-803 is a therapy developed and studied for the treatment of leukocyte adhesion deficiency type II (LAD II, also known as SLC35C1-CDG).

Key Points: 
  • AVTX-803 is a therapy developed and studied for the treatment of leukocyte adhesion deficiency type II (LAD II, also known as SLC35C1-CDG).
  • We are excited to announce the first patient was dosed in the LADDER pivotal trial.
  • This substantially advances the program toward an approved treatment option for patients and also a potential PRV, said Garry A. Neil, MD, President and Chief Executive Officer, Avalo Therapeutics.
  • The primary endpoint is the comparison of leukocyte function as determined by sialyl Lewis-X (SLx) antigen expression on leukocytes between treatment periods.

Trubify Artist Olivia Farabaugh Writes Songs to Inspire, and Heal

Retrieved on: 
Tuesday, April 19, 2022
Music, CIRS, Brain, Multi-system (rail), Songwriter, Human voice, Headache, Hope, Song, Arthralgia, Fatigue

LOS ANGELES, April 19, 2022 /PRNewswire/ -- Trubify the new music-streaming platformis teaming up with independent artist Olivia Farabaugh on April 29 to host a virtual benefit concert to support individuals with Chronic Inflammatory Response Syndrome.

Key Points: 
  • LOS ANGELES, April 19, 2022 /PRNewswire/ -- Trubify the new music-streaming platformis teaming up with independent artist Olivia Farabaugh on April 29 to host a virtual benefit concert to support individuals with Chronic Inflammatory Response Syndrome.
  • Like many singer-songwriters, Olivia Farabaugh is a confessional composer and performer who shares the ebb and flow of existence through her own experiences.
  • Trubify, in its mission to empower musicians, is thrilled and honored to present artists such as Olivia Farabaugh, who share their talents, their music, and their experiences to inspire us all.
  • Download the Trubify app , tune in, and help Farabaugh realize her dream of making the Transparent Music Project a reality.

Alladapt Announces Initiation of Encore Open-Label Extension Study for its Harmony Phase 1/2 Study of ADP101 for Treatment of Food Allergy

Retrieved on: 
Thursday, March 17, 2022
Food allergy, FA, Stanford University, Research, GLOBE, Patient, Allergy, Therapy, FDA, Disease, Food, Risk, COVID-19, Pediatrics, Diagnosis, Safety, Adrenaline, OLE, Asthma, Adult, Clinical trial, Multi-system (rail), Population, Salmon, Growth, Biotechnology, OIT, Allergen, Immunoglobulin E, Pharmaceutical industry, Encore, Harmony, Medicine

As an OLE study, Encore will enroll patients who completed the Harmony Phase 1/2 study.

Key Points: 
  • As an OLE study, Encore will enroll patients who completed the Harmony Phase 1/2 study.
  • The growth of our ADP101 program underscores our long-term commitment to deliver new treatment options for patients who are burdened by food allergy.
  • Encore is an open label extension study designed for subjects who successfully completed the Harmony Study.
  • The company is currently conducting the Harmony Study, a Phase 1/2, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of ADP101 for the treatment of food allergy in children and adults and the Encore Study, an open-label extension study for its Harmony study.